Market Overview

OPKO Completes Patient Recruitment in Second Phase 3 Trial of Rayaldy

OPKO Health (NYSE: OPK), has completed patient recruitment in the
second phase 3 trial of RayaldyTM to treat
patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic
kidney disease (CKD) and vitamin D insufficiency. This trial is the
second of two identical randomized, double-blind, placebo-controlled,
multi-site studies intended to establish the safety and efficacy of RayaldyTM as
a new treatment for SHPT in the targeted population. The endpoints of
both studies, which are being conducted in parallel, include vitamin D
status and changes in serum calcium, serum phosphorus and plasma intact
parathyroid hormone (PTH).

Each of the two pivotal phase 3 trials involves approximately 210
patients recruited at approximately 40 sites in the United States

See full press release

Posted-In: News Guidance Offerings Contracts M&A Global

 

Most Popular

Related Articles (OPK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free